Skip to main content

Table 5 Comorbidity profilea of early-diagnosed adult PKU patients in 2015 in Germany

From: Clinical burden of illness in patients with phenylketonuria (PKU) and associated comorbidities - a retrospective study of German health insurance claims data

ICD-10-GM code Comorbidity Early-diagnosed PKU population (n = 161)
%
Control population (n = 1,610)
%
PR (95% CI)
Z30 Encounter for contraceptive management 46.6 42.4 1.10 (0.92, 1.31)
Z12 Encounter for screening for malignant neoplasms 35.4 30.1 1.18 (0.94, 1.47)
N89 Other noninflammatory disorders of vagina 31.7 27.8 1.14 (0.90, 1.45)
J06 Acute upper respiratory infections of multiple and unspecified sites 29.2 27.6 1.06 (0.82, 1.36)
M54 Dorsalgia 26.1 22.6 1.15 (0.88, 1.52)
Z01 Encounter for other specified exam without complaint, suspected or reported dx 23.6 15.5 1.52 (1.13, 2.05) b
N94 Pain and other condition associated with female genital organs and menstrual cycle 18.0 12.9 1.39 (0.98, 1.98)
R10 Abdominal and pelvic pain 15.5 13.0 1.19 (0.81, 1.74)
J30 Vasomotor and allergic rhinitis 14.9 11.4 1.30 (0.88, 1.93)
A09 Infectious gastroenteritis and colitis, unspecified 14.9 9.9 1.51 (1.01, 2.25) b
N92 Excessive, frequent and irregular menstruation 14.3 10.7 1.34 (0.89, 2.00
F43 Reaction to severe stress, and adjustment disorders 13.7 7.8 1.75 (1.14, 2.67) b
H52 Disorders of refraction and accommodation 13.0 10.8 1.21 (0.79, 1.84)
F45 Somatoform disorders 13.0 9.3 1.40 (0.91, 2.15)
F32 Major depressive disorder, single episode 12.4 9.9 1.25 (0.81, 1.93)
E66 Overweight and obesity 11.8 7.1 1.67 (1.05, 2.63) b
M79 Other and unspecified soft tissue disorders, not elsewhere classified 11.2 5.5 2.05 (1.27, 3.31) b
F41 Other anxiety disorders 10.6 5.3 2.00 (1.22, 3.28) b
M99 Biomechanical lesions, not elsewhere classified 10.6 8.7 1.21 (0.75, 1.96)
T78 Adverse effects, not elsewhere classified 10.6 6.8 1.56 (0.96, 2.53)
D22 Melanocytic nevi 10.6 8.9 1.19 (0.74, 1.91)
  1. a Only comorbidities present in > 10% of PKU Patients are shown; a full listing of the top 50 comorbidities is provided in Additional file 1: Table S5
  2. bComorbidities that had a significant PR vs the control population